Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of LAM-001 in Adults With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

NCT05798923 is registered in ClinicalTrials.gov with IRulya Therapeutics Inc. as lead sponsor.

NCT NCT05798923
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05798923 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of LAM-001 in Adults With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Lead sponsor
IRulya Therapeutics Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
August 30, 2023
Completion date
February 28, 2029
Enrollment
85 (estimated)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary hypertension due to lung diseases and hypoxia